Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.

Shi, Jun; Zhao, Yan; Ishii, Takefumi; Hu, Wenyang; Sozer, Selcuk; Zhang, Wei; Bruno, Edward; Lindgren, Valerie; Xu, Mingjiang; Hoffman, Ronald

Shi, Jun; Zhao, Yan; Ishii, Takefumi; Hu, Wenyang; Sozer, Selcuk; Zhang, Wei; Bruno, Edward; Lindgren, Valerie; Xu, Mingjiang; Hoffman, Ronald.

Affiliation

Shi J; Section of Hematology/Oncology, Department of Medicine, University of Illinois College of Medicine, Chicago, Illinois 60612, USA.

Cancer Res ; 67(13): 6417-24, 2007 Jul 01.

Article in En | MEDLINE | ID: mdl-17616702

Subject(s)

Antigens, CD34/biosynthesis; Antimetabolites, Antineoplastic/pharmacology; Azacitidine/analogs & derivatives; Chromatin/chemistry; Chromatin/metabolism; Hydroxamic Acids/pharmacology; Primary Myelofibrosis/blood; Primary Myelofibrosis/drug therapy; Protein Synthesis Inhibitors/pharmacology; Antigens, CD34/metabolism; Azacitidine/pharmacology; Cell Movement; DNA (Cytosine-5-)-Methyltransferases/metabolism; Decitabine; Hematopoietic Stem Cells/metabolism; Homozygote; Humans; Mutation; Receptors, CXCR4/metabolism; Stem Cells/metabolism

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Azacitidine / Protein Synthesis Inhibitors / Chromatin / Antigens, CD34 / Primary Myelofibrosis / Hydroxamic Acids / Antimetabolites, Antineoplastic Limits: Humans Language: En Journal: Cancer Res Year: 2007 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links